Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00168740
Status:
COMPLETED
Last Update Posted:
2005-09-15
First Post:
2005-09-13
Brief Title:
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab Also Known as Rituxan IDEC-C2B8 IDEC-102
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 IDEC-102 in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Rituximab is an antibody made in a laboratory It binds to lymphoma cells and kills them Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks The patients tumors were measured before and after treatment Ten patients had a complete response and 70 patients had a partial response to rituximab The median duration of response was 112 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None